Therefore, structural differences between the p53–HLA-A2 and p53R175H–HLA-A2 complexes that disclosed the naturally altered p53 self-peptide to the T cells of cancer patients13,14 are restricted to the mutation site at P8. Here, TP53 is linked to cancer.